# Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost

> **NCT01896180** · PHASE2 · COMPLETED · sponsor: **Alleanza Pharmaceuticals, Inc.** · enrollment: 63 (actual)

## Conditions studied

- Primary Open Angle Glaucoma
- Ocular Hypertension
- Elevated Intraocular Pressure

## Interventions

- **DRUG:** ALZ-1101
- **DRUG:** Latanoprost

## Key facts

- **NCT ID:** NCT01896180
- **Lead sponsor:** Alleanza Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2014-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01896180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01896180, "Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01896180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*